GlassScriptPhysician profile
Jaya Sharma
NPI 1710184197
$6,583.22
in general payments reported to CMS, 2019-2025
41 companies · $1,746 in 2025
The $1,746 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $364 · 2021: $623 · 2022: $858 · 2023: $909 · 2024: $1,694 · 2025: $1,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,349.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,164.89 | 2019-2025 | Imfinzi, Lynparza, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $573.65 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Janssen Biotech, INC. | $389.71 | 2021-2025 | Erleada, Akeega, Balversa |
| Merck Sharp & Dohme LLC | $349.20 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $347.75 | 2019-2025 | Itovebi, Alecensa, Tecentriq Hybreza |
| Novartis Pharmaceuticals Corporation | $290.85 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $286.34 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $274.32 | 2020-2024 | Vyxeos |
| Seagen INC. | $271.95 | 2019-2023 | Tukysa |
| Celgene Corporation | $265.35 | 2019-2024 | Reblozyl |
| Lilly USA, LLC | $240.84 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $230.77 | 2019-2025 | |
| Tempus Ai, INC | $220.87 | 2024-2025 | Xt Cdx |
| Daiichi Sankyo INC. | $205.96 | 2022-2025 | Enhertu, Datroway |
| Incyte Corporation | $173.99 | 2021-2025 | Jakafi, Monjuvi |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaya Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.